To investigate the efficacy and safety of osimertinib plus savolitinib for patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations and de novo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results